MedTrace Logo

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-03-21

No results posted yet for this study

Summary

Primary Objective:

• To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.

Conditions

  • Sturge Weber Syndrome
  • Port-wine Mark

Interventions

DRUG

Timolol

0.5% timolol maleate ophthalmic gel-forming solution applied once

DRUG

Preservative free artificial tear gel.

Preservative free artificial tear gel applied topically twice a day.

Sponsors & Collaborators

  • University of Medicine and Dentistry of New Jersey

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Alex V Levin, MD, MHSc · Wills Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2019-01-31
Completion
2019-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533376 on ClinicalTrials.gov